A Study of the Transition From IV Cangrelor to Oral Prasugrel, and Prasugrel to Cangrelor, in Patients With Coronary Artery Disease.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2015
At a glance
- Drugs Cangrelor (Primary) ; Prasugrel
- Indications Coronary artery disease; Myocardial infarction; Thrombosis; Venous thromboembolism
- Focus Pharmacodynamics
- Sponsors The Medicines Company
- 31 Aug 2018 Biomarkers information updated
- 09 Oct 2013 Study completion announced in a media release issued by The Medicines Company.
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.